Steering vital health policy changes, my role at Boehringer Ingelheim ensures that innovative therapies for Lung & Lytics diseases are accessible within the CEE-region. My expertise in market access strategies emerges from a strong foundation in pharmacoeconomics and is further solidified by my tenure managing the Hematology, Immunology, and MS portfolios.
Case Study
Monday, October 06
11:50 am - 12:15 pm
Live in Berlin
Less Details
EHCI has been on the EU’s agenda for a couple of years now, however the progress has been rather slow. Taking into consideration the changing demographics and other factors, it is important for us as an industry to have the overview across the union to better assess the demand, pricing and other factors crucial for the strategy moving forward. So, what can we do with the existing information, and how can we as industry contribute to the development of this policy?
In this presentation you will learn: